Skip to main content
Equibles
BVS logo

BVS

Bioventus Inc.
$10.48 +0.63 (+6.40%) At close · Jul 2
Market Cap
$875.44M
Shares
83,534,785

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$10.48 Open$9.97 Day$9.88–10.49 52W$5.81–11.25 Avg vol 30d702K Short int1.9M · 2.3% float · 2.7d Short vol71% Last earningsMay 6, 2026 DataFeb 2021–Jul 2026 Filing10-Q · May 6
Equibles Rating blended score · not investment advice
Overall
Buy
Technical · trend & momentum Strong Buy
◦ 50 / 200-day cross no cross
+ Price vs 200-day avg +26% above
+ Price vs 50-day avg +10% above
◦ RSI (14) 66 · neutral
+ MACD trend positive
+ 52-week position 86% · near high
Sentiment · smart money Bearish
◦ Trend (MA cross) 50d $10 › 200d $8 — 50d above 200d
− Institutional flow 2 of 156 funds reported for Jun 30 · net -1.7K sh shares
◦ Insider flow No net insider activity over 90 days
− Short interest 2.31% of float · ▲ +4.8% MoM · 2.7 days cover
◦ Volume signal Volume near normal
+ Institution breadth 156 holders — near 3-yr high, broad support
Fundamentals Strong
− Revenue growth −1% Y/Y
+ Gross margin 68%, expanding
+ EPS growth +159% Y/Y
+ Free cash flow $72.1M
+ Valuation P/E 25.6 · below peers
− Balance sheet net debt $306.4M

Blended from price, positioning & fundamentals · daily-close · not investment advice.

Up next
Next earnings call
Aug 5, 2026 Est · unconfirmed · in 4 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed May 6, 2026
AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Guidance & track record
      Latest guidance · from the 8-K filed May 6, 2026
      Net sales · twelve months ending December 31, 2026 Initiated $600M – $610M
      prior FY $568.09M midpoint +6.5% Y/Y

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Strong Buy
      0 · 2 · 4
      50 / 200-day cross
      no cross Neutral
      Price vs 200-day avg
      +26% above Bullish
      Price vs 50-day avg
      +10% above Bullish
      RSI (14)
      66 · neutral Neutral
      MACD trend
      positive Bullish
      52-week position
      86% · near high Bullish
      Market signals — smart money & positioning
      Bearish · 2 of 6
      Trend (MA cross) No cross
      50d $10 › 200d $8 — 50d above 200d
      Institutional flow Distributing
      2 of 156 funds reported for Jun 30 · net -1.7K sh shares
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Rising
      2.31% of float · ▲ +4.8% MoM · 2.7 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      156 holders — near 3-yr high, broad support
      Price context
      position in its 52-week range
      52-wk low $6 Now $10 · 86% 52-wk high $11
      vs 200-day avg +26% vs 50-day avg +10%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from its earnings releases, calls, and filings
      Metric Latest Period YoY
      Cash from operations $8.9M Q1 —

      Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file

      Versus peers

      Medical Devices — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      BVS
      Bioventus Inc.
      this stock
      		$875.44M +40.9% +0.0% 25.6 2.3%
      ABT
      Abbott Laboratories
      		 $166.17B -23.5% +5.7% 26.7 1.3%
      SYK
      Stryker Corp
      		 $125.18B -6.8% +11.2% 37.8 1.6%
      MDT
      Medtronic plc
      		 $106.49B -12.7% +8.4% 22.3 1.4%
      BSX
      Boston Scientific Corp
      		 $67.09B -52.7% +5.5% 18.9 2.0%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Reducing
      Holders
      155
      % held
      60.2%
      Reported
      2 of 156
      Top holder
      Essex Woodlands Managemen…
      Held Float
      View
      Held by Funds
      Fund positions
      152
      View
      Short & Settlement
      Short Interest Rising
      Shares short
      1.9M
      Days to cover
      2.7d
      Change
      +87.6K sh
      View
      Short Volume
      Short vol %
      71%
      As of
      Jul 2, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      697
      Value
      $6.0K
      As of
      Jun 12, 2026
      View
      Off-Exchange
      Off-exchange %
      31.0%
      Week of
      May 4, 2026
      Off-exch Lit
      View
      Financials
      Financials
      Revenue (FY)
      $568.1M
      Net income (FY)
      $22.7M
      EPS diluted
      $0.33
      View
      Filings
      SEC Filings
      Latest
      Investor Event Transcript
      Filed
      Jun 30, 2026
      This year
      8
      View
      Proposed Sales
      Value
      $105.7K
      Shares
      12.0K
      Filed
      Mar 11, 2026
      View
      Earnings & Events
      Earnings Calls
      Last call
      Jun 8, 2026
      View
      Investor Relations
      Latest news
      Bioventus to Present at the Goldm…
      Published
      Jun 2, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      BVS +7.7% +22.6% +31.0% +11.0% +40.9%
      SPY +1.4% -1.3% +8.0% -0.3% +9.2%
      vs SPY +6.3% +23.8% +23.0% +11.3% +31.6%
      Key facts CIK 1665988 CUSIP 09075A108 13F (30d) 1 filings 1 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)